Previous 10 | Next 10 |
Thinly traded micro cap Aptinyx (APTX) jumps 49% after hours in reaction to positive results from a Phase 2 clinical trial evaluating NYX-783 in 153 patients with posttraumatic stress disorder ((PTSD)).NYX-783, an NMDA receptor modulator, showed statistically significant and clinica...
Clinically meaningful and statistically significant improvement on CAPS-5 Arousal and Reactivity Score observed with NYX-783 Clinically meaningful improvement from baseline on CAPS-5 Total Score observed in 50 mg dose arm Statistically significant separation of 50 mg f...
Virios Therapeutics has filed to raise $30 million in an IPO of its common stock. The firm is developing a proprietary formulation for the treatment of fibromyalgia, a pain condition. VIRI has achieved intriguing early efficacy results, received fast track review status and the IP...
Aptinyx (APTX) has recommenced patient recruitment in Phase 2 study of NYX-2925 in patients with fibromyalgia. Enrollment was suspended in March due to the pandemic in the U.S.Expects topline data in 1H of 2022.Fibromyalgia is a chronic condition characterized by widespread musculos...
Resuming study following suspension of enrollment due to escalation of COVID-19 pandemic Data readout expected in 1H 2022 Also on track to recommence separate Phase 2 study of NYX-2925 in painful DPN in 4Q 2020 Aptinyx Inc. (Nasdaq: APTX), a clinical-stage bi...
Quick Take Virios Therapeutics ( VIRI ) has filed to raise $34.5 million in an IPO of its common stock, according to an S-1 registration statement . The company is developing a drug treatment for fibromyalgia, a nerve pain condition. VIRI has generated interesting early stage efficacy r...
Aptinyx Inc (APTX) Q2 2020 Results Conference Call August 13, 2020 05:00 PM ET Company Participants Nick Smith - Senior Director, Corporate Development & IR Norbert Riedel - President & CEO Ashish Khanna - CFO & Chief Business Officer Andy Kidd - COO Kathryn King ...
Aptinyx (NASDAQ: APTX ) : Q2 GAAP EPS of -$0.27 beats by $0.01 . More news on: Aptinyx Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Completed enrollment in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in 4Q 2020 Recommencement of Phase 2 studies of NYX-2925 in chronic pain expected soon Conference call today at 5:00 p.m. ET Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceut...
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the 2020 Wedbush PacGrow Healthcare Virtual Conference. The presen...
News, Short Squeeze, Breakout and More Instantly...
Signature Bank (SBNY) is expected to report for Q3 2023 BHP Group Ltd. (BHP) is expected to report for Q1 2024 Sorrento Therapeutics Inc. (SRNEQ) is expected to report $-0.15 for Q3 2023 Baran Group Ltd. (BRANF) is expected to report for quarter end 2023-09-30 World Copper (WCUFF)...
GLG Life Tech Corporation (GLGLF) is expected to report for Q1 2024 Accenture plc Class A (Ireland) (ACN) is expected to report $3.14 for Q1 2024 Greenlane Holdings Inc. (GNLN) is expected to report $-2.7 for Q3 2023 iMedia Brands Inc. (IMBIQ) is expected to report for quarter end 202...
Axcella Health Inc. (AXLA) is expected to report for Q3 2023 Telekom Malaysia Bhd (MYTEF) is expected to report for quarter end 2023-09-30 Atento S.A. (ATTOF) is expected to report for Q3 2023 Scryb Inc Com (SCYRF) is expected to report for Q4 2023 BHP Group Ltd. (BHP) is expected...